1. CAS No:89778-27-8
2. Molecular Formula: C26H28ClNO.C6H8O7
3. Assay: 97.0%~103.0%
4. Appearance: White crystalline powder.
5. Usage:Originally developed to fight breast cancer, bodybuilders have used Fareston to successfully fight gynocomastia caused when testosterone converts to estrogen in the body and men grow breasts. This substance can be used for little else and other similar compounds, such as Nolvadex or Clomid, are much more effective in post-cycle-therapy.
(also known under its brand and trade name of Fareston) is a member of a category, family, and class of drugs that are known as SERMs (Selective Estrogen Receptor Modulators). SERMs fall under an even broader category of drugs that are known as anti-estrogens, and the cousin family of SERMs (that also fall under anti-estrogens) are aromatase inhibitors, commonly abbreviated as AIs. SERMs include compounds such as Nolvadex and Clomid (Clomiphene Citrate). Aromatase inhibitors (AIs) include compounds such as Arimidex ) Aromasin, (Femara). Although the two fall under the category of anti-estrogens, they are both sub-categories that branch off into their own families, as SERMs and AIs differ greatly in their mechanism of action within the human body concerning how they control or block Estrogen. There has been much misunderstanding and misconception in previous decades as to what each of these do, and this should always be first clarified to the reader before describing Toremifene.
Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the
actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene
citrate is FDA-approved for use in advanced (metastatic) breast cancer. It is also being evaluated for
prevention of prostate cancer under the brand name Acapodene.
It has already been covered that Toremifene is a SERM, and serves to block Estrogen at various receptor
sites in certain tissues within the body (breast tissue in particular). As a layman explanation, Toremifene
pretends to be a ‘fake’ Estrogen that occupies Estrogen receptors within breast tissue. With these
receptors occupied by Toremifene, real Estrogen cannot perform their jobs there.
Toremifene does not reduce total blood plasma levels of Estrogen. In addition to being antagonistic to
Estrogen receptors in breast tissue, it is also antagonistic to Estrogen at the hypothalamus gland
(this essentially ‘tricks’ the hypothalamus into thinking there is little or no circulating Estrogen levels in the
body, causing it to increase its manufacture of Testosterone so that it can utilize aromatization to restore
Toremifene is also agonistic to Estrogen receptors in other tissues in the body (within the liver in particular).
This means that whileToremifene will act as an anti-estrogen in breast tissue and the hypothalamus, it will
act as an Estrogen within the liver. This can have beneficial impacts especially during an anabolic steroid
cycle, such as improving and shifting cholesterol levels into a more favorable range.
(Fareston) is a non-steroidal selective Estrogen receptor modulator (SERM) that expresses both mixed agonistic as well as antagonistic properties in relation to Estrogen in different tissues and cells within the human body. Toremifene is a member of a family of compounds known as triphenylethylene compounds, which Nolvadex as well as Clomid (Clomiphene Citrate) are both also members of, and are both in particular very closely related compounds to each other.